Small Molecule SUMO Inhibition for Biomarker-Informed B Cell Lymphoma Therapy

Researchers reported that activated MYC signaling was an actionable molecular vulnerability in vitro and in a pre-clinical murine in vivo model of MYCdriven B cell lymphoma.